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SYNOPSIS 
In multivariable analysis, the interval between neoadjuvant therapy and surgery was not an 
independent predictor of postoperative complications in rectal cancer patients. Complications 
were associated with male sex, tumor location, open operative approach, and neoadjuvant 
chemoradiotherapy administered alone. 
 
  
3 
 
ABSTRACT 
Background.  Increasing the interval from completion of neoadjuvant therapy to surgery beyond 
8 weeks has been reported to increase complications. However, a recent study found that delay 
beyond 8 weeks is not associated with higher perioperative morbidity.  
Methods.  Patients who presented with a tumor within 15 cm of the anal verge in 2009–2015 
were grouped according to the interval between completion of neoadjuvant therapy and surgery: 
<8 weeks, 8 to 12 weeks, and >12 to 16 weeks. 
Results. Among 607 patients, the surgery was performed at <8 weeks in 317 patients, 8 to 12 
weeks in 229 patients, and >12 to 16 weeks in 61 patients. Patients who underwent surgery at 8 
to 12 weeks and patients who underwent surgery at <8 weeks had comparable rates of 
complications (37 and 44%, respectively).  Univariable analysis identified male sex, earlier date 
of diagnosis, tumor location within 5 cm of the anal verge, open operative approach, 
abdominoperineal resection, and use of neoadjuvant chemoradiotherapy alone to be associated 
with higher rates of complications. In multivariable analysis, male sex, tumor location within 5 
cm of the anal verge, open operative approach, and neoadjuvant chemoradiotherapy administered 
alone were independently associated with the presence of a complication. The interval between 
neoadjuvant therapy and surgery was not an independent predictor of postoperative 
complications. 
Conclusions. Delaying surgery beyond 8 weeks from completion of neoadjuvant therapy does 
not appear to increase surgical morbidity in rectal cancer patients.  
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INTRODUCTION 
Rectal cancer treatment is multimodal. The standard approach in North America includes 
preoperative chemoradiotherapy (chemoRT) for tumors of clinical stage II or III (cT3/4, cN+) 
based on MRI or endorectal ultrasound.1 This approach confers excellent local control, with 
local-recurrence rates less than 5%.2 The most common type of relapse is distant failure.3,4   
Following completion of neoadjuvant therapy, surgery is delayed for several weeks to 
allow the response to treatment to continue. In recent years, prolongation of the interval between 
completion of neoadjuvant therapy and surgery has gained popularity based on evidence that 
prolongation is associated with higher rates of downstaging and pathologic complete response.5-
10  However, surgeons have traditionally expressed concern over pelvic fibrosis associated with 
radiotherapy when surgery is delayed beyond 8 weeks, because pelvic fibrosis makes surgery 
more technically challenging and increases morbidity.  
The optimal time for operative intervention remains a topic of debate among clinicians.   
The current guidelines of the National Comprehensive Cancer Network recommend surgical 
intervention at 5 to 12 weeks.1 Two recent studies evaluating data from the National Cancer 
Database found that delaying surgery beyond 8 weeks was associated with a higher rate of 
positive surgical margins and a lower rate of sphincter preservation.11,12 The GRECCAR-6 trial 
found that in patients who underwent surgery at 11 weeks, the quality of the mesorectal resection 
specimen was poorer and the rate of complications was higher than in patients who underwent 
surgery at 7 weeks (45% vs. 32%).13 However, the difference in the rates of complications was 
attributable to medical rather than surgical comorbidity. A phase II trial of neoadjuvant FOLFOX 
in combination with chemoRT found that patients who underwent surgery at 12 to 26 weeks did 
not have higher rates of pelvic fibrosis or surgical morbidity.14   
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At Memorial Sloan Kettering Cancer Center (MSK), neoadjuvant strategies for rectal 
cancer include chemoRT alone, systemic chemotherapy alone, and the combination of 
chemotherapy and chemoRT, which is referred to as total neoadjuvant therapy (TNT).15 Deferral 
of surgery after an apparent complete clinical response has become commonplace,16 and an 
increasing proportion of patients undergo delayed resection following neoadjuvant therapy. 
Patients with near-complete response are often monitored for 8 to 12 weeks and even longer 
before having definitive surgery. In order to plan appropriate management and also to optimize 
clinical outcome, it is important to determine whether the timing of surgery influences surgical 
risk.  This study was aimed at comparing the rates of postoperative morbidity among patients 
who differed in the length of the interval from completion of neoadjuvant therapy to surgery. Our 
hypothesis was that postoperative morbidity is not higher in patients who undergo surgery more 
than 8 weeks after completion of neoadjuvant therapy.  
 
 
 
METHODS 
Patients 
A waiver of authorization was obtained from the institutional review board to review 
patient records. We searched an MSK database to identify patients seen at the MSK colorectal 
surgical oncology clinic between June 1, 2009, and March 1, 2015, with biopsy-proven 
nonmetastatic primary locally advanced rectal adenocarcinoma within 15 cm of the anal verge 
(based on proctoscopy), who received neoadjuvant therapy. Locally advanced rectal 
adenocarcinoma was defined in accordance with the guidelines of the National Comprehensive 
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Cancer Network as a stage cT3/cT4 N0 or cT(any) cN1/2 tumor based on endorectal ultrasound 
or MRI.1 Additionally, CT of the chest, abdomen, and pelvis was performed for local disease 
staging prior to initiation of treatment. Patients were excluded if they had previously undergone a 
surgical intervention for rectal cancer, had recurrent or metastatic disease at initial assessment or 
diagnosed during neoadjuvant treatment, or had complicated fistulizing inflammatory bowel 
disease in the rectum or perineum.   
 
Neoadjuvant Therapy 
The neoadjuvant regimen was chemotherapy alone, chemoRT alone, or TNT. 
Chemotherapy alone generally included fluorouracil in combination with oxaliplatin (FOLFOX) 
administered over a 4- to 6-month period prior to surgery. ChemoRT involved long-course 
radiation delivered in 28 fractions with concurrent infusional fluorouracil or oral capecitabine. 
TNT involved combinations of fluorouracil and oxaliplatin administered before or after 
chemoRT (as induction or consolidation chemotherapy, respectively).  Upon completion of 
neoadjuvant therapy, the decision on whether to proceed with surgery was based on the degree of 
clinical response to treatment, based on clinical, endoscopic, and radiological assessments. 
Timing of surgery throughout the study period was at the discretion of the surgical team. 
 
Clinical Response to Neoadjuvant Therapy 
Nonoperative management or deferral of surgery was part of the course of treatment for 
selected patients who had a clinical complete response to neoadjuvant therapy. The clinical and 
radiological features used to determine the presence of a clinical complete response have been 
described previously, as have the initial results of using nonoperative management for such 
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patients.16 Patients who did not undergo surgery upon completion of neoadjuvant therapy entered 
a surveillance protocol.  In cases where there was clinical concern for tumor regrowth or patient 
choice to move off a nonoperative approach, a delayed resection was performed.   
Patients who did not have a clinical complete response underwent radical resectional 
surgery, generally within 16 weeks of completing neoadjuvant therapy. The patients were 
grouped by length of time between the last day of receiving neoadjuvant treatment and the date 
of surgery: <8 weeks (28 to 55 days), 8 to 12 weeks (56 to 84 days), and >12 to 16 weeks (85 to 
112 days). All surgeries were performed by MSK surgeons according to the principles of 
anatomic mesorectal excision using either an open or a minimally invasive approach, defined as 
sharp mesorectal dissection under direct visualization and as laparoscopic or robotically assisted 
surgery, respectively. A diverting ileostomy was created at the surgeon’s discretion.   
 
Pathological Response to Neoadjuvant Therapy 
Pathology data were collected from analyses of resection specimens performed shortly 
after surgery. The specimens were evaluated in accordance with standard protocols for rectal 
cancer pathology.17 Pathologic complete response to neoadjuvant treatment was defined as 
absence of viable tumor cells in the final resection specimen.  
 
Complications 
Data on complications that occurred in the first 90 days after surgery were collected from 
a prospectively maintained institutional database18 and from patient records, including inpatient, 
outpatient, discharge summary, and readmission notes and correspondence. Complications were 
graded according to the Clavien-Dindo classification system.8 Complications due to adjuvant 
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chemotherapy or subsequent surgery unrelated to rectal cancer were deemed nonattributable and 
were excluded. Clavien-Dindo grade 1–5 complications were grouped in the category “any 
complications”. Anastomotic leaks (leak or dehiscence) were identified on radiographic imaging 
with contrast (e.g., CT scan with contrast or Gastrografin enema) or direct visualization with 
endoscopy. Such investigations were not performed routinely but were prompted in cases of  
clinical suspicion.  
 
Statistical Analyses 
Clinical and pathological data were grouped according to standard thresholds. Groups 
were compared using the chi-square test for trend for categorical data and the Kruskal-Wallis test 
for continuous data, with a significance level of P < 0.05. Associations between individual 
variables and the presence of any complications after surgery were evaluated with univariable 
and multivariable binary logistic regression. A significance threshold of P < 0.05 was set for 
inclusion in the multivariable model. The data were analyzed using SPSS software (IBM). 
 
 
RESULTS 
Of the patients who attended the colorectal surgical clinic at MSK between June 1, 2009, 
and March 1, 2015, 798 received neoadjuvant therapy. Following neoadjuvant therapy, 657 
(82%) patients underwent surgery within 12 months, of whom 607 (76% of 798) had surgery 
within 16 weeks. Deferral of surgery beyond 16 weeks was due to entry into a watch-and-wait 
protocol or to various medical or surgical reasons (e.g., treatment of medical comorbidities), and 
those patients were excluded from analysis.  The clinical and pathological characteristics of 
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patients who underwent rectal resection within 16 weeks of completing neoadjuvant therapy are 
listed in Table 1.  
We did not observe any significant relationships between time to surgery and 
postoperative morbidity when time was analyzed as a continuous variable (data not shown). 
Patients were therefore grouped by categories considered clinically relevant, in agreement with 
previous reports.11-13 Three hundred seventeen patients (52%) had surgery <8 weeks after 
completing neoadjuvant therapy (mean, 46 ± 7.4 [standard deviation] days), 229 patients (38%) 
had surgery at 8 to 12 weeks (mean, 65 ± 7.8 days), and 61 patients (10%) had surgery at >12 to 
16 weeks (mean, 93 ± 7.9 days). 
Patients who underwent surgery ≥8 weeks after completion of neoadjuvant therapy were 
significantly more likely to be older than 75 years, to have begun treatment in 2014-2015, and to 
have a tumor within 5 cm of the anal verge (requiring abdominoperineal resection). They were 
also more likely to have received TNT and to have had a diverting ileostomy after a sphincter-
saving procedure. Minimally invasive surgery was less common in patients who underwent 
surgery at >12 to 16 weeks (Table 1). 
Complications occurred in 256 (42%) of patients (Table 2). Surgery at >12 to 16 weeks 
was associated with a significantly higher overall rate of complications (56%) than surgery at <8 
weeks (44%) or surgery at 8–12 weeks (37%) (P = 0.02 [Chi square for trend]). However, the 
three groups of patients did not differ significantly in the rates of surgical site infection (SSI), 
grade 3–5 complications, or anastomotic leak. They also did not differ significantly in median 
length of hospital stay or the proportion of patients whose hospital stay exceeded 7 days (Table 
2). Patients who underwent surgery at <8 weeks and patients who underwent surgery at 8–16 
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weeks had comparable rates of complications (Tables S1 and S2 in the Supplement). Subanalysis 
of data for 281 patients who received chemoRT alone produced similar results (Tables S3 and S4 
in the Supplement).  
Further subgroup analysis showed that among patients who had sphincter-preserving low 
anterior resection, those who underwent surgery at >12 to 16 weeks had a higher rate of 
complications (53% vs. 41% and 31%; P = 0.025). Likewise, among patients with a poor 
response to treatment (absence of T downstaging), those who underwent surgery at >12 to 16 
weeks had a higher rate of complications (66% vs. 44% and 33%; P = 0.008). No other 
relationships between time to surgery and complications were observed for other subgroups. 
The data on the incidence of complications in relation to the patients’ clinical and 
pathological characteristics are listed in Table 3. Associations were observed between the 
occurrence of any complication and male sex, earlier year of diagnosis, tumor within 5 cm of the 
anal verge, open surgery, abdominoperineal resection, use of ileostomy after low anterior 
resection, and use of chemoRT alone. Grade 3–5 complications were more common in patients 
without T or N downstaging. The incidence of SSI was associated with earlier year of diagnosis, 
open surgery, abdominoperineal resection, use of chemoRT alone, increasing ypN stage, and 
absence of N downstaging. Anastomotic leak after low anterior resection was associated with 
open surgery (P < 0.05).   
The results of binary logistic regression analysis for factors potentially associated (P < 
0.1) with the occurrence of any complication after surgery are listed in Table 4. On univariable 
logistic regression, male sex, earlier year of diagnosis (2009–2011), tumor within 5 cm of the 
anal verge, advanced ypT stage (ypT 4), open surgery, abdominoperineal resection, and 
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chemoRT administered alone were associated with complications. In multivariable analysis, 
male sex, tumor within 5 cm of the anal verge, open surgery, and chemoRT alone were 
independently associated with complications.   
 
DISCUSSION 
Time to surgery did not appear to increase the risk of complications on univariate or 
multivariable analysis. We did observe a weak association with higher complication rates in 
patients who underwent surgery at >12 to 16 weeks, but those patients were also more likely to 
be older than 75 years, to undergo abdominoperineal resection, and to undergo open (rather than 
minimally invasive) surgery—factors likely to confound an ostensible association with 
complications.  
Our findings are consistent with those of the GRECCAR-6 trial13 in that any potential 
increase in complications associated with a delay in surgery did not include changes in the rates 
of SSI, grade 3–5 complications, or anastomotic leak. Similarly, a recent phase II trial reported 
no increase in surgical morbidity or operator-perceived technical difficulty for surgery performed 
between 12 and 26 weeks.14 These results contrast to an extent with the recent reports based on 
National Cancer Database audit data in which surgery beyond 8 weeks was associated with an 
increased rate of positive surgical margins.11,12  We observed no increase in resection margin 
positivity with deferred surgery. However, similarly to those studies, we did note an increased 
proportion of abdominoperineal resections in the later surgery groups. Rather than stemming 
from the possible technical difficulty of achieving sphincter preservation when surgery is 
delayed, this increase is probably attributable to a longer wait time for maximal response to 
treatment and to the extensive planning required for this complex surgery.   
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Grade 3–5 complications are the most clinically relevant, and it is reassuring that their 
rates remained comparable across the time-to-surgery groupings.  Of interest, grade 3–5 
complications and SSI were associated with poor response to neoadjuvant therapy (absence of T 
or N downstaging), suggesting that delaying surgery may not be advisable in patients with a poor 
treatment response. Complications were also associated with male sex and tumor location within 
5 cm of the anal verge (requiring abdominoperineal resection), which are well-known risk 
factors,19 and with the type of neoadjuvant regimen. In multivariable analysis, chemoRT was 
associated with higher rates of complications compared to TNT or chemotherapy alone. 
Minimally invasive surgery was associated with fewer complications than open surgery.   
A small proportion (10%) of the patients in our study underwent surgery between 12 and 
16 weeks following completion of neoadjuvant therapy. All of those patients had an incomplete 
response to treatment, but surgery was delayed because of various medical or surgical factors 
that affected surgery planning or because of patient preference. This subgroup had a relatively 
high proportion of older patients who were more likely to have medical comorbidities and a 
relatively high proportion of patients with lower tumors requiring abdominoperineal resection. 
We included these patients in our analyses because the above factors are relevant to the 
incidence of postoperative complications, and exclusion of this subgroup could potentially bias 
results.  
In addition to its retrospective design and analysis, the study’s limitations include 
potentially narrow generalizability. Nonoperative management was offered to patients who had a 
clinical complete response after neoadjuvant therapy, and 24% of the patients treated for locally 
advanced rectal adenocarcinoma at MSK during 2009–2015 did not undergo surgery within 16 
weeks. This large proportion of patients in nonoperative management protocols may complicate 
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comparisons with series from other institutions. The analysis is also potentially limited by 
temporal trends in postoperative outcomes, as the overall rate of complications, the rate of SSI, 
and the rate of anastomotic leaks declined in the later years of the study. Another potentially 
confounding factor was that a higher proportion of patients who had surgery at ≥8 weeks 
received TNT. Because our study was retrospective, we were not able to obtain details of 
treatment decisions with respect to the selection of a specific neoadjuvant approach or operative 
technique.  Finally, an additional limitation was the fact that some potentially important 
covariates known to be associated with perioperative outcomes were not available. These include 
detailed information on body habitus/BMI, patient comorbidities, and smoking status. 
 The strengths of our study include the large cohort of patients, who received treatment in 
a modern setting in which nonoperative management was increasingly commonplace. As 
nonoperative management gains popularity, it is of critical importance to accurately detail the 
outcomes for patients who do not achieve a complete response to neoadjuvant therapy. Although 
the data presented here suggest that delaying surgery does not increase surgical morbidity in 
general, it is not known whether delaying surgery in patients with a poor treatment response may 
compromise outcomes. In this study, we observed higher rates of grade 3–5 complications in 
patients without T or N downstaging (P < 0.05) and a similar trend in patients with lower tumor 
regression (P < 0.1).  Further research is required to clarify the impact of delaying surgery in 
such patients. There may be a role for a two-step assessment of response to treatment, with the 
goal of identifying patients with a poor response earlier in order to plan surgery. In our own 
practice, we currently advocate full clinical and endoscopic staging at approximately 8 weeks. If 
a complete or near-complete response is observed and the patient prefers to delay surgery, 
reassessment is performed at around 12 weeks with a view to considering nonoperative 
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management (watch and wait). For patients with an obvious incomplete treatment response at 12 
weeks and significant tumor bulk remaining, no advantage can likely be gained from further 
delay of surgery.  Another novel aspect of the study is the demonstration that, in comparison 
with chemoRT alone, extended neoadjuvant therapy (TNT) does not appear to compromise 
surgical outcomes.  
In summary, our findings indicate that time to surgery from completion of neoadjuvant 
therapy for locally advanced rectal adenocarcinoma does not appear to be a significant risk factor 
for postoperative complications. Tumor location, the type of neoadjuvant treatment, the operative 
approach, and response to neoadjuvant therapy are likely more important.  
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SUPPLEMENT 
 
Table S1. Patient characteristics in relation to the timing of surgery among patients who received either 
chemoradiotherapy alone or total neoadjuvant therapy.  
Table S2. Postoperative complications in relation to the timing of surgery among patients who received 
either chemoradiotherapy alone or total neoadjuvant therapy. 
Table S3. Patient characteristics in relation to the timing of surgery among patients who received 
chemoradiotherapy alone.  
Table S4. Postoperative complications in relation to the timing of surgery among patients who received 
chemoradiotherapy alone.  
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